Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Clinical Trials

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Phase 3

Not yet recruiting

Conditions: Pancreas Cancer

Interventions: Drug: Fluorouracil
Radiation: Dose-escalated Radiation Therapy
Drug: Irinotecan Hydrochloride
Procedure: Biopsy Procedure
Drug: leucovorin calcium
Procedure: Computed Tomography
Drug: Oxaliplatin
Procedure: Magnetic Resonance Imaging
Drug: Irinotecan Sucrosofate
Other: Questionnaire Administration
Drug: Gemcitabine
Drug: Nab paclitaxel
Radiation: Radiation Therapy
Drug: Capecitabine
Other: Observation Activity
Procedure: Biospecimen Collection

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: NRG Oncology

Target Recruit Count: 356

Registration Number: NCT06958328

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer

Interventions: Drug: ONO-4578
Drug: Opdivo®
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil
Drug: Bevacizumab

First Posted Date: 2025-04-29

Last Posted Date: 2025-04-29

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 144

Registration Number: NCT06948448

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Oxaliplatin
Drug: Irinotecan
Drug: Folinic Acid
Drug: 5-Fluorouracil (5-FU)
Drug: NC410
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 20

Registration Number: NCT06941857

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Phase 2

Recruiting

Conditions: Locally Recurrent Rectal Cancer

Interventions: Radiation: Conventional Radiotherapy
Drug: Capecitabine
Drug: 5-fluorouracil
Drug: folinic acid
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Cetuximab
Drug: Bevacizumab
Radiation: Hypofractionated radiotherapy
Drug: PD-1 antibody

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Fudan University

Target Recruit Count: 221

Registration Number: NCT06928584

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Phase 3

Not yet recruiting

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Metastatic Gastric Adenocarcinoma or Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma